A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonicanhydrase IX and vascular endothelial growth factor

Strahlentherapie und Onkologie

Volumn 190, Issue 3, 2014, Pages 276-282

  Ostheimer, C ^a   Bache, M ^a   Guttler A ^a   Kotzsch, M ^b   Vordermark, D ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Biological markers; Hemoglobin; Overall survival; Prognostic factors; Vascular endothelial growth factor

Indexed keywords

CARBONATE DEHYDRATASE IX; CISPLATIN; NAVELBINE; OSTEOPONTIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PILOT STUDY; PROTEIN BLOOD LEVEL; TUMOR VOLUME; VERY ELDERLY; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PILOT PROJECTS; PROGNOSIS; RADIATION TOLERANCE; STATISTICS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896385809     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0484-1     Document Type: Article

References (53)

1. Höckel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28:6-41
2. Bayer C, Vaupel P (2012) Acute versus chronic hypoxia in tumors. Strahlenther Onkol 188:616-627
3. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239 (Pubitemid 47101660)
4. Zips D, Böke S, Kroeber T et al (2011) Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol 187:306-310
5. Vaupel P, Kelleher DK, Höckel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29-35 (Pubitemid 32522235)
6. Ostheimer C, Vordermark D (2013) Osteopontin - an indicator of tumor hypoxia and treatment resistance. In: Vordermark D (ed) Hypoxia: causes, types and management. Nova Publishers, New York
7. Vordermark D, Brown JM (2003) Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 179:801-811 (Pubitemid 37509467)
8. Le QT (2007) Identification and targeting hypoxia in head and neck cancer - a brief overview of current approaches. Int J Radiat Oncol Biol Phys 69:S56-S58
9. Bache M, Kappler M, Said HM et al (2008) Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 15:322-338 (Pubitemid 351266939)
10. Masahi U, Hideo S (2013) Visualization and treatment of the HIF-1-active microenvironments in tumors: drug design and application of oxygen-dependent degradable probes for molecular imaging of HIF-1-active microenvironments. In: Vordermark D (ed) Hypoxia: causes, types and management, 1st edn. Nova Publishers, New York, pp 221-235
11. Schilling D, Bayer C, Emmerich K et al (2012) Basal HIF-1α expression levels are not predictive of radiosensitivity of human cancer cell lines. Strahlenther Onkol 188:353-358
12. Le QT, Kong C, Lavori PW et al (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167-175 (Pubitemid 47247510)
13. Kim SJ, Rabbani ZN, Dewhirst MW et al (2005) Expression of HIF-1α, CA-IX, VEGF and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325-335 (Pubitemid 41139145)
14. Ilie M, Mazure NM, Hofman V et al (2010) High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 25:1627-1635
15. Hoogsteen IJ, Marres HA, Bussink J et al (2007) Tumor microenvironment in head and neck squamous cell carcinoma: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 29:591-604 (Pubitemid 47324777)
16. Zhu Y, Denhardt DT, Cao H et al (2005) Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555-6563 (Pubitemid 41486638)
17. Le QT, Chen E, Salim A et al (2006) An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12:1507-1514
18. Overgaard J, Eriksen JG, Nordsmark M et al (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764 (Pubitemid 41430716)
19. Mack PC, Redman MW, Chansky K et al (2008) SWOG: Lower osteopontin plasma levels are associated with superior outcomes in advanced nonsmall-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771-4776
20. Blasberg JD, Pass HI, Goparaju CM et al (2010) Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28:936-941
21. Raja R, Kale S, Thorat D et al (2013) Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF-1α-mediated VEGF-dependent angiogenesis. Oncogene doi:10.1038/onc.2013.171
22. Senger DR, Ledbetter SR, Claffey KP et al (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the av b 3 integrin osteopontin, and thrombin. Am J Pathol 149:293-305 (Pubitemid 26231000)
23. Solberg TD, Nearman J, Mullins J et al (2008) Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys 72:918-926
24. Zhao X, Liu X, Guo W et al (2010) Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression. Chin J Cancer 13:881-866
25. Beasley NJ, Wykoff CC, Watson PH et al (2001) Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61:5262-5267 (Pubitemid 32681562)
26. Le QT, Sutphin PD, Raychaudhuri S et al (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67 (Pubitemid 36109716)
27. Snitcovsky I, Leitão GM, Pasini FS et al (2009) Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Arch Otolaryngol Head Neck Surg 135:807-811
28. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549
29. Helbig L, Yaromina A, Sriramareddy SN et al (2012) Prognostic value of HIF-1α expression during fractionated irradiation. Strahlenther Onkol 188:1031-1037
30. Dellas K, Bache M, Pigorsch SU (2008) Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervival cancer. Strahlenther Onkol 284:169-174 (Pubitemid 351365780)
31. Bache M, Reddemann R, Said HM et al (2006) Immunohistochemical detection of osteopontin in advanced head and neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1-alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 66:1481-1487
32. Dunst J, Becker A, Lautenschläger C (2002) Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 178:436-441 (Pubitemid 34847423)
33. Dunst J, Stadler P, Becker A et al (2001) Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 177:469-473 (Pubitemid 32861427)
34. Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243-259 (Pubitemid 34044509)
35. Chang YS, Kim HJ, Chang J (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373-380 (Pubitemid 47285428)
36. Karadag F, Gulen ST, Karul AB et al (2011) Osteopontin as a marker of weight loss in lung cancer. Scand J Clin Lab Invest 71:690-694
37. Bache M, Kappler M, Wichman H et al (2010) Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10:132-140
38. Soliman M, Yaromina A, Appold S et al (2013) GTV differentially impacts locoregional control of non small-cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWELL trial. Radiother Oncol 106:299-304
39. Ball DL, Fisher RJ, Burmeister BH et al (2013) The complex relationship between lung tumor volume and survival in patients with non small-cell lung cancer treated by definite radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 106:305-311
40. Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143-158 (Pubitemid 43144358)
41. Takenaka M, Hanagiri T, Shinohara S et al (2012) Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small cell lung cancer. Clin Lung Cancer 31:S1525-S7304
42. Potter CP, Harris AL (2003) Diagnostic, prognostic and therapeutic of carbonic anhydrases in cancer. Br J Cancer 89:2-7 (Pubitemid 36897927)
43. Mayer A, Höckel M, Vaupel P (2008) Endogenous hypoxia markers: case not proven! Adv Exp Med Biol 614:127-136
44. Weber GF (2011) The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 8:263-288
45. De Schutter H, Landuyt W, Verbeken E et al (2005) The prognostic value of the hypoxia markers CA IX and GLUT I and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy. BMC Cancer 5:42-53
46. Byers LA, Holsinger FC, Kies MS et al (2010) Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9:1755-1763
47. Yaromina A, Quennet V, Zips D et al (2009) Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human suqmous cell carcinoma (hSCC) xenografts. Int J Radiat Biol 85:971-980
48. Zips D, Zöphel K, Abolmaali N et al (2012) Exploratory prospective trial of hypoxia-specific PET-imaging during radiochemotherapy in patients with locally advanced head-and-neack cancer. Radiother Oncol 105:21-28
49. Mönnich D, Troost EG, Kaanders JH et al (2013) Correlation between tumor oxygenation and (18) F-fluoromisonidazole PET data simulated based on microvessel images. Acta Oncol 52:1308-1313
50. Erpolat, Gocun PO, Akmansu M et al (2013) Hypoxia-related molecules HIF-1á, CA9, and osteopontin. Predictors of survival in patients with high-grade glioma. Strahlenther Onkol 189:147-154
51. Dehing-Oberije C, Aerts H, Yu S et al (2011) Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 81:360-368
52. Staab A, Fleischer M, Loeffler J et al (2011) Small interfering RNA targeting HIF-1α reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 187:252-259
53. Vordermark D (2010) Hypoxia-specific targets in cancer therapy: role of splice variants. BMC Med 12:1741-7015